JP2017536342A - タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物 - Google Patents

タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物 Download PDF

Info

Publication number
JP2017536342A
JP2017536342A JP2017518848A JP2017518848A JP2017536342A JP 2017536342 A JP2017536342 A JP 2017536342A JP 2017518848 A JP2017518848 A JP 2017518848A JP 2017518848 A JP2017518848 A JP 2017518848A JP 2017536342 A JP2017536342 A JP 2017536342A
Authority
JP
Japan
Prior art keywords
group
disease
compound
phenyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536342A5 (enExample
Inventor
ペシャンスキ，マルク
ブロンデル，ソフィー
ニッサン，グザヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Association Francaise Contre les Myopathies
Original Assignee
Association Francaise Contre les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association Francaise Contre les Myopathies filed Critical Association Francaise Contre les Myopathies
Publication of JP2017536342A publication Critical patent/JP2017536342A/ja
Publication of JP2017536342A5 publication Critical patent/JP2017536342A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017518848A 2014-10-08 2015-10-07 タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物 Pending JP2017536342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306578 2014-10-08
EP14306578.7 2014-10-08
PCT/EP2015/073141 WO2016055517A1 (en) 2014-10-08 2015-10-07 Novel aminopyridine compounds useful as inhibitors of protein prenylation

Publications (2)

Publication Number Publication Date
JP2017536342A true JP2017536342A (ja) 2017-12-07
JP2017536342A5 JP2017536342A5 (enExample) 2018-09-13

Family

ID=51799057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518848A Pending JP2017536342A (ja) 2014-10-08 2015-10-07 タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物

Country Status (9)

Country Link
US (1) US10654838B2 (enExample)
EP (1) EP3204380B1 (enExample)
JP (1) JP2017536342A (enExample)
CN (1) CN107001315A (enExample)
BR (1) BR112017007178A2 (enExample)
DK (1) DK3204380T3 (enExample)
ES (1) ES2751623T3 (enExample)
IL (1) IL251568A0 (enExample)
WO (1) WO2016055517A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131807A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
KR20220151634A (ko) 2020-03-06 2022-11-15 버텍스 파마슈티칼스 인코포레이티드 Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
CA3190609A1 (en) 2020-08-26 2022-03-03 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525281A (ja) * 2003-05-08 2006-11-09 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ピリジニルアセトニトリル類
JP2007522233A (ja) * 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525281A (ja) * 2003-05-08 2006-11-09 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ピリジニルアセトニトリル類
JP2007522233A (ja) * 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOZALBES, R. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, JPN6019018160, 2008, pages 3124 - 3132, ISSN: 0004039143 *

Also Published As

Publication number Publication date
US20170305892A1 (en) 2017-10-26
EP3204380A1 (en) 2017-08-16
IL251568A0 (en) 2017-06-29
WO2016055517A1 (en) 2016-04-14
CN107001315A (zh) 2017-08-01
US10654838B2 (en) 2020-05-19
ES2751623T3 (es) 2020-04-01
DK3204380T3 (da) 2019-11-04
BR112017007178A2 (pt) 2017-12-19
EP3204380B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
Staben et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors
ES2424642T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
US10695347B2 (en) Pyrimidine derivative and use thereof
US20080176866A1 (en) Novel hetaryl-phenylenediamine-pyrimidines as protein kinase inhibitors
JP2017536342A (ja) タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物
CZ300984B6 (cs) Benzazolové deriváty, jejich použití a farmaceutický prostredek
Coumar et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification
NO20110523L (no) Fremgangsmate for a fremstille substituerte pyrimidiner
KR20090026264A (ko) 측쇄에 스피로 고리 구조를 갖는 신규 인다졸 유도체
AU2003261807A1 (en) Azaarene derivatives
EA019524B1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
CN105283454A (zh) 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
US20150152088A1 (en) Alkynyl heteroaromatic compound and use thereof
CA3030070A1 (en) Heterocyclic compound used as fgfr inhibitor
Shiao et al. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor
MX2010013606A (es) Diazacarbazoles y metodos de uso.
TW201014841A (en) Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors
US12145923B2 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
SA516370989B1 (ar) مركبات بيريميدين مستبدلة واستخدامها كمثبطات syk
US10975082B2 (en) Inhibitor of FLT3 kinase and use thereof
Xie et al. Discovery of 2-amino-7-sulfonyl-7 H-pyrrolo [2, 3-d] pyrimidine derivatives as potent reversible FGFR inhibitors with gatekeeper mutation tolerance: design, synthesis, and biological evaluation
US10266535B2 (en) Inhibitor of FLT3 kinase and use thereof
Zhang et al. Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors
EP3810136A1 (en) Oga inhibitor compounds

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107